Insulinoma other imaging findings: Difference between revisions

Jump to navigation Jump to search
No edit summary
(Mahshid)
 
(19 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Insulinoma}}
{{Insulinoma}}
{{CMG}}{{AE}}{{PSD}}
{{CMG}}{{AE}}{{ADS}}


==Overview==
==Overview==
There are no other imaging findings associated with [disease name].
The other imaging studies include [[Positron Emission Tomography|positron emission tomography]] ([[PET]]) and [[somatostatin receptor]] [[Scintigraphy]] (SRS) which are [[nuclear]] studies used for detecting [[Somatostatin receptor 2|somatostatin receptor especially subtype 2]] using radioisotopes of [[Gallium]]. The increased uptake of [[Radioligand|radioligands]] is suggestive of [[insulinoma]]. The [[metastasis]] also shows the increased uptake. The [[sensitivity]] of [[PET]] is increased by doing a [[CT scan]] coupled with [[PET]] scan. The [[Sensitivity (tests)|sensitivity]] of SRS is 50 to 60% as insulinomas have less [[Somatostatin receptor 2|somatostatin subtype 2 receptor]] which is detected by the test.


OR
==Other Imaging Findings==
 
===Positron emission tomography|Positron Emission Tomography===
[[File:Pet insulinoma.gif|thumb|center| Insulinoma-PET Scan.;Case courtesy of Radswiki, Radiopaedia.org, rID: 11670]]
*[[Positron]] emitting [[radioisotopes]] of [[Gallium]] such as 68 [[Gallium]]-DOTATAC, 68 [[Gallium]]-DOTATATE, and 68 [[Gallium]]-DOTANAC can be used to detect the uptakes in areas of increased [[somatostatin receptors]]. The [[Sensitivity (tests)|sensitivity]] is increased when it is coupled with [[CT]] scan although it is not approved for routine use in the United States.<ref name="pmid25493261">{{cite journal |vauthors=Sadowski SM, Neychev V, Cottle-Delisle C, Merkel R, Yang LA, Quezado MM, Chang R, Kebebew E |title=Detection of insulinoma using (68)Gallium-DOTATATE PET/CT: a case report |journal=Gland Surg |volume=3 |issue=4 |pages=E1–5 |year=2014 |pmid=25493261 |pmc=4244512 |doi=10.3978/j.issn.2227-684X.2014.10.02 |url=}}</ref><ref name="pmid17401086">{{cite journal |vauthors=Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R, Virgolini IJ |title=68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT |journal=J. Nucl. Med. |volume=48 |issue=4 |pages=508–18 |year=2007 |pmid=17401086 |doi= |url=}}</ref><ref name="pmid22984220">{{cite journal |vauthors=Haug AR, Cindea-Drimus R, Auernhammer CJ, Reincke M, Wängler B, Uebleis C, Schmidt GP, Göke B, Bartenstein P, Hacker M |title=The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors |journal=J. Nucl. Med. |volume=53 |issue=11 |pages=1686–92 |year=2012 |pmid=22984220 |doi=10.2967/jnumed.111.101675 |url=}}</ref>
*[[Positron emission tomography]] ([[PET]]) may be helpful in the diagnosis of [[insulinoma]]. Findings on a [[PET scan]] suggestive of insulinoma include:
**Increased uptake in the affected part of the [[pancreas]].
**[[Metastasis]] can also be detected in the same way.


[Imaging modality] may be helpful in the diagnosis of [disease name]. Findings on an [imaging modality] suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].
===Somatostatin receptor scintigraphy===


==Other Imaging Findings==
*There are no other imaging findings associated with [disease name].


*[Imaging modality] may be helpful in the diagnosis of [disease name]. Findings on an [imaging modality] suggestive of/diagnostic of [disease name] include:
[[File:Srs inslnoma.gif|200px|thumb|center|Insulinoma-Octreoscan;Case courtesy of Radswiki, Radiopaedia.org, rID: 11670]]
**[finding 1]
*Somatostatin receptor [[scintigraphy]](SRS) may be helpful in the diagnosis of [[Pancreatic neuroendocrine tumor|pancreatic neuroendocrine tumor<nowiki/>s]] including insulinomas. As many insulinomas do not express [[Somatostatin receptor 2|somatostatin subtype 2 receptors]], it is less sensitive(50 to 60%).<ref name="pmid8944566">{{cite journal| author=Zimmer T, Stölzel U, Bäder M, Koppenhagen K, Hamm B, Buhr H et al.| title=Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. | journal=Gut | year= 1996 | volume= 39 | issue= 4 | pages= 562-8 | pmid=8944566 | doi= | pmc=1383270 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8944566  }} </ref><ref name="pmid9854595">{{cite journal| author=Proye C, Malvaux P, Pattou F, Filoche B, Godchaux JM, Maunoury V et al.| title=Noninvasive imaging of insulinomas and gastrinomas with endoscopic ultrasonography and somatostatin receptor scintigraphy. | journal=Surgery | year= 1998 | volume= 124 | issue= 6 | pages= 1134-43; discussion 1143-4 | pmid=9854595 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9854595  }} </ref> <ref name="McAuleyDelaney2005">{{cite journal|last1=McAuley|first1=G.|last2=Delaney|first2=H.|last3=Colville|first3=J.|last4=Lyburn|first4=I.|last5=Worsley|first5=D.|last6=Govender|first6=P.|last7=Torreggiani|first7=W.C.|title=Multimodality preoperative imaging of pancreatic insulinomas|journal=Clinical Radiology|volume=60|issue=10|year=2005|pages=1039–1050|issn=00099260|doi=10.1016/j.crad.2005.06.005}}</ref><ref name="pmid7513113">{{cite journal| author=Behr T, Becker W, Koch W, Grebmeier J, Wolf F| title=[Somatostatin receptor scintigraphy in neuroendocrine tumors exemplified by a patient with hepatic metastases of gastrinoma]. | journal=Z Gastroenterol | year= 1994 | volume= 32 | issue= 2 | pages= 100-4 | pmid=7513113 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7513113  }} </ref><ref name="pmid9825476">{{cite journal |vauthors=Jensen RT, Gibril F, Termanini B |title=Definition of the role of somatostatin receptor scintigraphy in gastrointestinal neuroendocrine tumor localization |journal=Yale J Biol Med |volume=70 |issue=5-6 |pages=481–500 |year=1997 |pmid=9825476 |pmc=2589266 |doi= |url=}}</ref>
**[finding 2]
Findings on an SRS suggestive of insulinoma include:
**[finding 3]
*Increased uptake of pentetreotide (synthetic [[somatostatin]] analog)
*Increased uptake in sites of [[metastasis]], commonly in [[hepatic]] involvement


==References==
==References==
Line 23: Line 29:
{{WH}}
{{WH}}
{{WS}}
{{WS}}
[[Category:Medicine]]
[[Category:Endocrinology]]
[[Category:Up-To-Date]]
​​
[[Category:Radiology]]
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Gastroenterology]]
[[Category:Surgery]]

Latest revision as of 02:07, 27 November 2017

Insulinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Insulinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

X-ray

Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Insulinoma other imaging findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Insulinoma other imaging findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Insulinoma other imaging findings

CDC on Insulinoma other imaging findings

Insulinoma other imaging findings in the news

Blogs on Insulinoma other imaging findings

Directions to Hospitals Treating Insulinoma

Risk calculators and risk factors for Insulinoma other imaging findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2]

Overview

The other imaging studies include positron emission tomography (PET) and somatostatin receptor Scintigraphy (SRS) which are nuclear studies used for detecting somatostatin receptor especially subtype 2 using radioisotopes of Gallium. The increased uptake of radioligands is suggestive of insulinoma. The metastasis also shows the increased uptake. The sensitivity of PET is increased by doing a CT scan coupled with PET scan. The sensitivity of SRS is 50 to 60% as insulinomas have less somatostatin subtype 2 receptor which is detected by the test.

Other Imaging Findings

Positron emission tomography|Positron Emission Tomography

Insulinoma-PET Scan.;Case courtesy of Radswiki, Radiopaedia.org, rID: 11670

Somatostatin receptor scintigraphy

Insulinoma-Octreoscan;Case courtesy of Radswiki, Radiopaedia.org, rID: 11670

Findings on an SRS suggestive of insulinoma include:

References

  1. Sadowski SM, Neychev V, Cottle-Delisle C, Merkel R, Yang LA, Quezado MM, Chang R, Kebebew E (2014). "Detection of insulinoma using (68)Gallium-DOTATATE PET/CT: a case report". Gland Surg. 3 (4): E1–5. doi:10.3978/j.issn.2227-684X.2014.10.02. PMC 4244512. PMID 25493261.
  2. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R, Virgolini IJ (2007). "68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT". J. Nucl. Med. 48 (4): 508–18. PMID 17401086.
  3. Haug AR, Cindea-Drimus R, Auernhammer CJ, Reincke M, Wängler B, Uebleis C, Schmidt GP, Göke B, Bartenstein P, Hacker M (2012). "The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors". J. Nucl. Med. 53 (11): 1686–92. doi:10.2967/jnumed.111.101675. PMID 22984220.
  4. Zimmer T, Stölzel U, Bäder M, Koppenhagen K, Hamm B, Buhr H; et al. (1996). "Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas". Gut. 39 (4): 562–8. PMC 1383270. PMID 8944566.
  5. Proye C, Malvaux P, Pattou F, Filoche B, Godchaux JM, Maunoury V; et al. (1998). "Noninvasive imaging of insulinomas and gastrinomas with endoscopic ultrasonography and somatostatin receptor scintigraphy". Surgery. 124 (6): 1134–43, discussion 1143-4. PMID 9854595.
  6. McAuley, G.; Delaney, H.; Colville, J.; Lyburn, I.; Worsley, D.; Govender, P.; Torreggiani, W.C. (2005). "Multimodality preoperative imaging of pancreatic insulinomas". Clinical Radiology. 60 (10): 1039–1050. doi:10.1016/j.crad.2005.06.005. ISSN 0009-9260.
  7. Behr T, Becker W, Koch W, Grebmeier J, Wolf F (1994). "[Somatostatin receptor scintigraphy in neuroendocrine tumors exemplified by a patient with hepatic metastases of gastrinoma]". Z Gastroenterol. 32 (2): 100–4. PMID 7513113.
  8. Jensen RT, Gibril F, Termanini B (1997). "Definition of the role of somatostatin receptor scintigraphy in gastrointestinal neuroendocrine tumor localization". Yale J Biol Med. 70 (5–6): 481–500. PMC 2589266. PMID 9825476.

Template:WH Template:WS ​​